Unique ID issued by UMIN | UMIN000031161 |
---|---|
Receipt number | R000035587 |
Scientific Title | A exploratory study to evaluate the efficacy of the narrow band UVB therapy by Area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofuji |
Date of disclosure of the study information | 2018/04/01 |
Last modified on | 2019/03/07 17:25:52 |
A exploratory study to evaluate the efficacy of the narrow band UVB therapy by Area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofuji
the narrow band UVB therapy by Area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofuji
A exploratory study to evaluate the efficacy of the narrow band UVB therapy by Area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofuji
the narrow band UVB therapy by Area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofuji
Japan |
papuloerythroderma of Ofuji
Dermatology |
Others
NO
To evaluate the clinical efficacy of narrow band UVB therapy by area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofuji
Efficacy
amaunt of change with Body Surface Area of erythema after irradiation 24 times
amaunt of change with erythema and papules after irradiation 24 times
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
Irradiation frequency, once a day, three times a week or twice a week, and irradiating 24 times in total by 10 weeks.
One dose shall be 1/2 of the minimum erythema dose.
40 | years-old | <= |
85 | years-old | > |
Male and Female
Patients diagnosed with papuloerythroderma of Ofuji
1.Patients with malignant tumor complications
2.Patient with complication of skin malignancy or previous medical history
3.Patients with high cancer risk
4.Patients diagnosed with eczema secondary erythroderma (senile erythroderma), chronic prurigo, atopic dermatitis, drug eruption, lichen planus, eosinophilia syndrome, cutaneous amyloidosis, cutaneous lymphoma , leukemia
5.Patients undergoing Cyclosporine oral administration, etretinate orally,immunosuppressive therapy treatment
6. patients undergoing oral corticosteroid treatment with 21 mg or more per day in terms of prednisolone
7.Patients whose usage, dose of oral treatment, topical treatment has been changed within 2 weeks
8.Patients taking drugs that cause photosensitivity, patients with outstanding photosensitivity
9.Patients who have received UVB ultraviolet radiation therapy within 3 months
10.Patients who participated in other clinical trials within 4 months
11.patients judged inappropriate
10
1st name | |
Middle name | |
Last name | Satoshi Nishiyama |
Kobe University Graduate School of Medicine
Department of Dermatology
7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo Prefecture, JAPAN
078-382-6134
dermatol@med.kobe-u.ac.jp
1st name | |
Middle name | |
Last name | Satoshi Nishiyama |
Kobe University Graduate School of Medicine
Department of Dermatology
7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo Prefecture, JAPAN
078-382-6134
dermatol@med.kobe-u.ac.jp
Kobe University Graduate School of Medicine
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
NO
2018 | Year | 04 | Month | 01 | Day |
Unpublished
Terminated
2018 | Year | 02 | Month | 05 | Day |
2018 | Year | 05 | Month | 01 | Day |
2018 | Year | 02 | Month | 05 | Day |
2019 | Year | 03 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035587